Alligator Bioscience AB Asset Resilience Ratio
Alligator Bioscience AB asset resilience ratio. Alligator Bioscience AB (ATORX) has an Asset Resilience Ratio of 56.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Alligator Bioscience AB to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alligator Bioscience AB (2007–2025)
Asset resilience ratio of Alligator Bioscience AB from 2007 to 2025. This chart shows how Alligator Bioscience AB's Asset Resilience Ratio has changed over time. Read Alligator Bioscience AB debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Alligator Bioscience AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Alligator Bioscience AB (ATORX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr62.20 Million | 56.24% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr62.20 Million | 56.24% |
Asset Resilience Insights
- Very High Liquidity: Alligator Bioscience AB maintains exceptional liquid asset reserves at 56.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Alligator Bioscience AB Industry Peers by Asset Resilience Ratio
Compare Alligator Bioscience AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Alligator Bioscience AB Asset Resilience Ratio by Year (2007–2025)
Alligator Bioscience AB asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Alligator Bioscience AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.24% | Skr62.20 Million ≈ $6.69 Million |
Skr110.60 Million ≈ $11.90 Million |
-5.40pp |
| 2024-12-31 | 61.64% | Skr64.31 Million ≈ $6.92 Million |
Skr104.34 Million ≈ $11.23 Million |
+5.82pp |
| 2023-12-31 | 55.82% | Skr66.12 Million ≈ $7.12 Million |
Skr118.45 Million ≈ $12.75 Million |
-1.56pp |
| 2022-12-31 | 57.38% | Skr97.31 Million ≈ $10.47 Million |
Skr169.58 Million ≈ $18.25 Million |
-26.10pp |
| 2021-12-31 | 83.48% | Skr278.15 Million ≈ $29.93 Million |
Skr333.20 Million ≈ $35.86 Million |
+15.46pp |
| 2020-12-31 | 68.02% | Skr103.34 Million ≈ $11.12 Million |
Skr151.94 Million ≈ $16.35 Million |
-28.36pp |
| 2019-12-31 | 96.38% | Skr299.85 Million ≈ $32.27 Million |
Skr311.13 Million ≈ $33.48 Million |
+20.98pp |
| 2018-12-31 | 75.40% | Skr383.13 Million ≈ $41.23 Million |
Skr508.16 Million ≈ $54.69 Million |
+1.85pp |
| 2017-12-31 | 73.55% | Skr472.92 Million ≈ $50.89 Million |
Skr643.03 Million ≈ $69.20 Million |
-20.51pp |
| 2016-12-31 | 94.06% | Skr659.14 Million ≈ $70.93 Million |
Skr700.78 Million ≈ $75.42 Million |
+94.06pp |
| 2015-12-31 | 0.00% | Skr1.00K ≈ $107.62 |
Skr416.26 Million ≈ $44.80 Million |
-51.18pp |
| 2008-12-31 | 51.18% | Skr10.00 Million ≈ $1.08 Million |
Skr19.54 Million ≈ $2.10 Million |
-29.54pp |
| 2007-12-31 | 80.72% | Skr38.62 Million ≈ $4.16 Million |
Skr47.85 Million ≈ $5.15 Million |
-- |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using N… Read more